JPS62167725A - 卒中治療剤 - Google Patents

卒中治療剤

Info

Publication number
JPS62167725A
JPS62167725A JP62001981A JP198187A JPS62167725A JP S62167725 A JPS62167725 A JP S62167725A JP 62001981 A JP62001981 A JP 62001981A JP 198187 A JP198187 A JP 198187A JP S62167725 A JPS62167725 A JP S62167725A
Authority
JP
Japan
Prior art keywords
verapamil
stroke
rats
diltiazem
nifedipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62001981A
Other languages
English (en)
Japanese (ja)
Inventor
フランク・ダブリユー・マークークス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JPS62167725A publication Critical patent/JPS62167725A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
JP62001981A 1986-01-10 1987-01-09 卒中治療剤 Pending JPS62167725A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US818505 1986-01-10
US06/818,505 US4654372A (en) 1986-01-10 1986-01-10 Method for using verapamil for treating stroke

Publications (1)

Publication Number Publication Date
JPS62167725A true JPS62167725A (ja) 1987-07-24

Family

ID=25225695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62001981A Pending JPS62167725A (ja) 1986-01-10 1987-01-09 卒中治療剤

Country Status (8)

Country Link
US (1) US4654372A (2)
EP (1) EP0229644B1 (2)
JP (1) JPS62167725A (2)
AT (1) ATE81006T1 (2)
CA (1) CA1284950C (2)
DE (1) DE3781904T2 (2)
ES (1) ES2046178T3 (2)
GR (1) GR3005998T3 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871731A (en) * 1987-10-07 1989-10-03 Marion Laboratories, Inc. Captopril and diltiazem composition and the like
DE3737741A1 (de) * 1987-11-06 1989-05-18 Goedecke Ag Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid
EP0429676B1 (en) * 1989-06-16 1996-09-18 Santen Pharmaceutical Co., Ltd Drug for improving brain function
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
EP3917515A1 (en) * 2019-01-29 2021-12-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
AU2021255701B2 (en) * 2020-04-17 2025-12-04 Honeybrains, Llc Compositions and methods for treating neuropsychiatric disorders
WO2026002967A1 (en) 2024-06-24 2026-01-02 Universität Linz Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130517A (ja) * 1983-12-16 1985-07-12 Mitsui Pharmaceut Inc アレルギ−性鼻炎治療剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568677A (en) * 1983-07-23 1986-02-04 Pfizer Inc. 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130517A (ja) * 1983-12-16 1985-07-12 Mitsui Pharmaceut Inc アレルギ−性鼻炎治療剤

Also Published As

Publication number Publication date
ES2046178T3 (es) 1995-04-01
US4654372A (en) 1987-03-31
DE3781904D1 (de) 1992-11-05
DE3781904T2 (de) 1993-02-25
CA1284950C (en) 1991-06-18
EP0229644A2 (en) 1987-07-22
EP0229644B1 (en) 1992-09-30
ATE81006T1 (de) 1992-10-15
GR3005998T3 (2) 1993-06-07
EP0229644A3 (en) 1989-11-23

Similar Documents

Publication Publication Date Title
CA2761156C (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
RU2340342C2 (ru) СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
BRPI0618239A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico
WO2006096434A2 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
ES2210957T3 (es) Composiciones farmaceuticas que contienen norastemizol.
JPS62167725A (ja) 卒中治療剤
WO2009155777A1 (zh) 法舒地尔化合物的用途、方法及其药物组合物
ES2215990T3 (es) Antagonistas del receptor 5-ht2 para tratar enfermedades venosas.
DE69024053T2 (de) Behandlung zur ermässigung von ödem und muskelschäden.
US4618621A (en) Method for treating medical conditions involving cerebral ischemia
DE69635754T9 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
JP2003510356A (ja) Nk1受容体アンタゴニストとgaba構造類縁体との共働的組合せ体
US6239162B1 (en) Method for treating depression
US4696924A (en) Method for using diltiazem for treating stroke
US4696934A (en) Method for using nifedipine for treating stroke
JPH05194217A (ja) 抗高血圧組み合わせ医薬
DE60019591T2 (de) Behandlung oder hemmung von koronarimplantat vasospasm
Meyer et al. The novel dihydronaphthyridine Ca2+ channel blocker CI-951 improves CBF, brain pHi, and EEG recovery in focal cerebral ischemia
JPS5865224A (ja) アテロ−ム性動脈硬化症の処置方法及び組成物
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
BR112014015276B1 (pt) Combinação de (3s,3s) 4,4-dissulfanodiilbis(ácido 3-aminobutano 1-sulfônico) e um segundo agente anti-hipertensivo
EP0254313B1 (en) Use of ketamine for the manufacturing of medicaments for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
JPH11513386A (ja) β−受容体遮断薬とオピオイドとの新規な組合せ物
JPS59157021A (ja) 動脈硬化症予防治療剤
JP2001520194A (ja) うつ病治療のためのモキソニジンの使用